Fulcrum Therapeutics, Inc. (FULC) Discusses New Clinical Data From the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease December 7, 2025 7:00 AM EST

Company Participants

Alexander Sapir - CEO, President & Director Iain Fraser - Senior Vice President of Early Development

Conference Call Participants

Matthew Biegler - Oppenheimer & Co. Inc., Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division James Condulis - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Alexander Sapir CEO, President & Director

Good morning, everybody. Thank you all for joining us this morning. And I’d like to thank everybody who’s online as well. We’ve got a fairly robust number of people online. So thank you all for joining us virtually as well.

My name is Alex Sapir, I’m the Chairman – I’m sorry, I’m the CEO and President, not Chairman, CEO and President of Fulcrum Therapeutics.

This is a really exciting day for Fulcrum, but I think more importantly, it’s an even more exciting day for patients and the sickle cell community at large, really because of the potential that this drug has to possibly truly transform patients’ lives around the world. And so I think for that reason, we’re so excited that you have been able to join us.

Before we get started, I just wanted to remind everybody that today’s presentation will include some forward looking statements, which are based on current expectations and subject to risks and uncertainties. Actual results may differ materially, and we encourage you to review the full disclaimer on this slide together with the Risk Factors in Fulcrum’s most recent filings with the SEC.

So I’d like to introduce my fellow speakers

Recommended For You